Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Short term Debt (2017 - 2025)

Historic Short term Debt for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $10.1 million.

  • Innate Pharma's Short term Debt rose 517.29% to $10.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.1 million, marking a year-over-year increase of 517.29%. This contributed to the annual value of $9.3 million for FY2024, which is 320.56% down from last year.
  • Per Innate Pharma's latest filing, its Short term Debt stood at $10.1 million for Q2 2025, which was up 517.29% from $9.3 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Short term Debt peaked at $35.2 million during Q4 2021, and registered a low of $2.1 million during Q4 2022.
  • Its 5-year average for Short term Debt is $13.0 million, with a median of $9.6 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Innate Pharma's Short term Debt was 127730.66% (2021), while the steepest drop was 9988.06% (2021).
  • Innate Pharma's Short term Debt (Quarter) stood at $35.2 million in 2021, then plummeted by 93.9% to $2.1 million in 2022, then skyrocketed by 348.33% to $9.6 million in 2023, then dropped by 3.21% to $9.3 million in 2024, then increased by 8.67% to $10.1 million in 2025.
  • Its Short term Debt was $10.1 million in Q2 2025, compared to $9.3 million in Q4 2024 and $9.6 million in Q2 2024.